Chemomab Therapeutics (NASDAQ: CMMB), is a clinical-stage biotech company, focusing on discovery and development of innovative therapeutics for fibrosis-related diseases.
Chemomab is making great strides with its novel CM-101 proprietary platform, which hinders the fundamental function of the soluble chemokine CCL24 as a regulator of major inflammatory and fibrotic pathways in multiple fibrosis-related disorders.
CM-101, the company’s lead clinical candidate, is a first-in-class monoclonal antibody that targets CCL24. Chemomab has shown that CM-101 interferes with the underlying biology of fibrosis using a novel and differentiated mechanism of action.
Chemomab is actively advancing CM-101 into phase 2 studies to treat patients with liver fibrosis (Primary Sclerosing Cholangitis) and patients suffering from skin and lung fibrosis (Systemic Sclerosis).
Chemomab is making great strides with its novel CM-101 proprietary platform, which hinders the fundamental function of the soluble chemokine CCL24 as a regulator of major inflammatory and fibrotic pathways in multiple fibrosis-related disorders.
CM-101, the company’s lead clinical candidate, is a first-in-class monoclonal antibody that targets CCL24. Chemomab has shown that CM-101 interferes with the underlying biology of fibrosis using a novel and differentiated mechanism of action.
Chemomab is actively advancing CM-101 into phase 2 studies to treat patients with liver fibrosis (Primary Sclerosing Cholangitis) and patients suffering from skin and lung fibrosis (Systemic Sclerosis).
Location: Israel, Tel Aviv District, Tel Aviv
Employees: 11-50
Total raised: $10M
Founded date: 2011
Investors 3
| Date | Name | Website |
| - | Altium Cap... | altiumcap.... |
| - | Shavit Cap... | shavitcapi... |
| - | OrbiMed | orbimed.co... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 04.12.2017 | Series B | $10M | - |
Mentions in press and media 28
| Date | Title | Description |
| 02.10.2024 | ROTH to Host 3rd Annual Healthcare Opportunities Conference on October 9 in New York City | Conference to Feature Leading Healthcare Companies and Institutional Investors for 1x1/Small Group Meetings and Panels NEW YORK, Oct. 02, 2024 (GLOBE NEWSWIRE) -- via IBN -- ROTH Capital Partners, LLC (“ROTH”), www.roth.com, is pleased to a... |
| 12.01.2023 | Revive Therapeutics Ltd. Closes $4.3 Million Offering | - |
| 30.11.2022 | Revive Therapeutics Ltd. Announces Offering of Up to $5 Million | - |
| 17.12.2021 | Chemomab Therapeutics Announces Expected Appointment of Dale R. Pfost as Chairman of the Board | TEL AVIV, Israel, Dec. 16, 2021 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab) a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory d... |
| 03.12.2021 | Chemomab Therapeutics Names David M. Weiner, MD as Interim Chief Medical Officer | TEL AVIV, Israel, Dec. 3, 2021 /PRNewswire/ -- Chemomab Therapeutics Ltd. (NASDAQ: CMMB), (Chemomab) a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases... |
| 02.12.2021 | Chemomab Announces FDA Clearance of Its IND Application for CM-101, a First-In-Class CCL24 Neutralizing Antibody for the Treatment of Primary Sclerosing Cholangitis | TEL AVIV, Israel, Dec. 2, 2021 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory disease... |
| 12.11.2021 | Chemomab Therapeutics Announces Third Quarter 2021 Financial Results and Provides a Corporate Update | TEL AVIV, Israel, Nov. 12, 2021 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseas... |
| 08.11.2021 | Chemomab Therapeutics Names Donald R. Marvin Chief Financial Officer, Executive Vice President and Chief Operating Officer | TEL AVIV, Israel, Nov. 8, 2021 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab) a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases... |
| 27.09.2021 | Chemomab Therapeutics : Announces Collaboration with Leeds University to Further Elucidate the Role of CCL24 in Vascular Damage Associated with Systemic Sclerosis | TEL AVIV, Israel, Sept. 27, 2021 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) ("Chemomab"), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrotic and inflamm... |
| 02.09.2021 | Chemomab Therapeutics Announces Appointment of Dale Pfost as Chief Executive Officer USA - English USA - English |
Show more